

FACT SHEET

COMPANY PROFILE

Vita 34 is a pioneer amongst the private umbilical cord blood banks in Europe and it is the largest stem cell bank in the German-speaking countries. The company is active in two business segments, Stem Cell Banking and Biotechnology, and apart from Germany is currently represented in the European and global markets in a total of 29 countries via subsidiaries and cooperation partners. With its core business, the cryo-preservation of stem cells from umbilical cord blood and tissue, Vita 34 is targeted towards expecting parents, who wish to have the extremely vital stem cells preserved for their children immediately after birth as a provision. As a complete provider in the field of stem cell banking, Vita 34 covers the entire value chain: This encompasses collection logistics, preparation and the permanent storage of umbilical cord blood and tissue, as well as the professional dispensing of stem cell transplants.

SHARE CHART



FINANCIAL CALENDAR

- Aug 29, 2019** Publication half-yearly financial report
Nov 21, 2019 Publication quarterly statement (call-date Q3)

MANAGEMENT BOARD



Dr. Wolfgang Knirsch



Falk Neukirch

SUPERVISORY BOARD

- › Frank Köhler (Chairman) › Gerrit Witschaß (Vice-chairman of the Supervisory Board)
 › Dr. med. Mariola Söhngen › Steffen Richtscheid

STOCK FUNDAMENTALS

ISIN	DE000A0BL849
WKN	A0BL84
Share type	Ordinary
Bloomberg Code	V3V@GR
Reuters Code	V3VG.DE
Ticker	V3V
Branch	Pharma
Index	CDAX, Prime All Share, Technology All Share
Segment	Prime Standard
Last Dividend	0.16 (for 2017)
No. of shares	4,145,959
Market Cap	EUR 55.56 mn
52 week high	16.05 EUR
52 week low	10.10 EUR
Stock exchanges	Frankfurt Stock Exchange

SHAREHOLDER STRUCTURE

1.42%	Management + SB
3.01%	PBKM
8.57%	Dr. Gerth
11.64%	MKBV / Koehler Invest
75.36%	Free float

FACT SHEET

ANNUAL FIGURES

	2012	2013	2014	2015	2016	2017 ¹	2018
EUR k							
Revenue	13,603	13,554	13,786	14,169	16,290	19,192	20,409
Cost of sales	(5,559)	(5,491)	(5,911)	(7,681)	(7,669)	(8,391)	(8,435)
Gross profit	8,044	8,063	7,875	6,488	8,620	10,801	11,974
Other operating income	747	1,389	1,665	4,284	1,608	717	716
Selling expenses	(5,770)	(4,697)	(4,419)	(4,842)	(5,122)	(5,430)	(4,925)
Administrative expenses	(3,082)	(2,896)	(3,292)	(3,993)	(3,925)	(4,956)	(4,805)
Other operating expenses	(681)	(390)	(139)	(324)	(401)	(991)	(329)
Net operating income	(742)	1,469	1,690	1,613	780	141	2,631
Finance revenue	91	79	103	100	143	44	44
Finance costs	(204)	(205)	(96)	(126)	(194)	(200)	(891)
Earnings before taxes	(855)	1,343	1,697	1,587	687	(154)	1,784
Income tax income/expense	246	(555)	(707)	115	(71)	(171)	(952)
Period result after taxes	(609)	788	990	1,702	617	(325)	832
Earning per share	(0.20)	0.28	0.37	0.67	0.14	(0.09)	(0.20)

¹ The comparative figures were restated due to the effects of the first-time application of IFRS 15. Information on the adjustments to the prior-year figures can be found in note 2.3 of the notes to the consolidated financial statements.

QUARTERLY FIGURES

EUR k	2016		2017			2018			
	Q3	Q4	Q1	Q2*	Q3*	Q4	Q1	Q2	Q3
Revenue	4,013	4,256	4,081	4,072	5,600	5,437	5,076	5,100	5,375
Cost of sales	(1,721)	(1,966)	(1,632)	(1,908)	(2,619)	(2,231)	(2,146)	(2,256)	(2,143)
Gross profit on sales	2,291	2,289	2,448	2,164	2,980	3,206	2,930	2,844	3,232
Other operating income	559	361	241	192	137	147	101	246	87
Marketing and selling expenses	(1,304)	(1,333)	(1,161)	(1,269)	(1,470)	(1,530)	(1,278)	(1,390)	(1,138)
Administrative expenses	(1,014)	(1,041)	(1,072)	(1,482)	(1,224)	(1,178)	(1,206)	(1,243)	(1,278)
Other operating expenses	(45)	(277)	(10)	(910)	30	(101)	(5)	(83)	(136)
Net operating profit/loss (EBIT)	489	(1)	445	(1,304)	450	546	541	374	767
Finance revenue	20	60	17	13	9	7	10	24	6
Finance costs	(23)	(80)	(24)	(17)	(64)	(95)	(64)	(77)	(52)
Earnings before/taxes	460	(63)	437	(1,365)	353	421	488	321	721
Income tax expense	(178)	249	(157)	42	(179)	123	(180)	(85)	(216)
Period result / Total comprehensive income for the year after tax	282	187	280	(1,324)	174	545	308	236	505
Earnings per share (EUR)**	0.10	0.06	0.10	(0.44)	0.06	0.19	0.07	0.06	0.12

* The comparative figures presented have been restated to reflect the initial application of IFRS 15. Information on the restatement of figures presented for the previous year is provided in note 2.2 of the notes to the interim financial statements.

** Information for the period result attributable to ordinary equity holders of the parent

Vita 34 AG

Deutscher Platz 5a
04103 Leipzig
Deutschland

Tel.: +49 (0)341 48792-40
Fax: +49 (0)341 48792-39
info@vita34.de
www.vita34.de

Contact Investor Relations

Dr. Wolfgang Knirsch and Falk Neukirch
Tel.: +49 (0)341 48792-40
Fax: +49 (0)341 48792-39
M: ir@vita34group.de